Shailee Shah, MD
Neurology · Nashville, TNNPI 1659765840
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $27,145 of the $40,078 with a category attached, or 67.7%. 16 manufacturers reported payments, led by AstraZeneca at 42.3% of the total.
Across 62 payments — averaging $646.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$17K
- Genentech USA, Inc.$12K
- Amgen$7K
- TG Therapeutics, Inc.$2K
- Catalyst Pharmaceuticals, Inc.$1K
- Nevro Corp.$288
- plus $863 from 10 others
What the payments were for
- Consulting fees$27,14568%
- Speaking & faculty fees$8,53021%
- Travel & lodging$1,3953%
- Food & beverage$2,9497%
- Education$600%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 18 | $16,945 |
| Genentech USA, Inc. | 11 | $11,680 |
| Amgen(2 entities) | 13 | $6,782 |
| TG Therapeutics, Inc. | 4 | $2,258 |
| Catalyst Pharmaceuticals, Inc. | 2 | $1,262 |
| Nevro Corp. | 2 | $288 |
| Abbott | 2 | $253 |
| Inspire Medical Systems, Inc. | 1 | $149 |
| UCB, Inc. | 1 | $139 |
| Acadia Pharmaceuticals Inc | 1 | $85 |
| Biogen | 1 | $60 |
| SK Life Science, Inc. | 1 | $53 |
| Teva Pharmaceuticals USA, Inc. | 2 | $51 |
| Novartis | 1 | $29 |
| Sanofi | 1 | $23 |
| Altathera Pharmaceuticals LLC | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$40,078 in reported general payments places this provider in the 85th percentile of 361 neurology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BafiertamMonomethyl Fumarate | 12 | $74,743 |
| Dalfampridine ErDalfampridine | 69 | $24,357 |
| Aimovig AutoinjectorErenumab-Aooe | 12 | $8,467 |
| FingolimodFingolimod Hcl | 12 | $2,529 |
| Gabapentin | 38 | $803 |
| Baclofen | 52 | $458 |
| Oxcarbazepine | 11 | $318 |
Paid to pharmacies, not to this prescriber.
Other neurology in Nashville
- Harold MosesNashville$438K
- Daniel ClaassenNashville$285K
- Francesca BagnatoNashville$167K
- Philip CharlesNashville$132K
- Benjamin HoffmanNashville$124K
- Joy DerwenskusNashville$107K
- James EatonNashville$85K
- Elizabeth FerlugaNashville$77K
- Britt StoneNashville$75K
- Lavanya NagineniNashville$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.